Haemonetics Stock Cash Per Share

HAE Stock

USD 94.40 1.07 1.15%

Haemonetics fundamentals help investors to digest information that contributes to Haemonetics' financial success or failures. It also enables traders to predict the movement of Haemonetics Stock. The fundamental analysis module provides a way to measure Haemonetics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Haemonetics stock.

		Last Reported	Projected for Next Year
	Cash Per Share	3.42	1.98

As of May 4, 2024, Cash Per Share is expected to decline to 1.98.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Haemonetics Company Cash Per Share Analysis

Haemonetics' Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.

Cash Per Share

Total Cash

Average Shares

More About Cash Per Share | All Equity Analysis

Current Haemonetics Cash Per Share

4.79 X

Most of Haemonetics' fundamental indicators, such as Cash Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Haemonetics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Haemonetics Cash Per Share Driver Correlations

Understanding the fundamental principles of building solid financial models for Haemonetics is extremely important. It helps to project a fair market value of Haemonetics Stock properly, considering its historical fundamentals such as Cash Per Share. Since Haemonetics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Haemonetics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Haemonetics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Short Term Investments	Common Stock	Long Term Debt	Good Will	Property Plant Equipment	Current Deferred Revenue	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Accumulated Depreciation	Short Long Term Debt	Cash And Equivalents	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.61	0.86	0.24	0.91	0.59	0.96	0.97	0.04	0.92	-0.6	0.57	0.91	0.97	0.52	0.3	-0.83	0.92	0.74	0.59	-0.32	-0.56	0.69	-0.78	0.69	-0.6
Total Stockholder Equity	0.61		0.29	0.63	0.59	0.87	0.44	0.63	0.13	0.59	-0.85	0.64	0.35	0.53	0.77	-0.03	-0.37	0.38	0.44	0.39	-0.57	-0.28	0.34	-0.18	0.23	0.06
Net Debt	0.86	0.29		-0.1	0.69	0.33	0.95	0.75	0.04	0.86	-0.23	0.61	0.94	0.92	0.39	0.65	-0.94	0.94	0.73	0.61	-0.21	-0.58	0.68	-0.81	0.71	-0.51
Retained Earnings	0.24	0.63	-0.1		0.18	0.36	0.01	0.25	-0.16	0.31	-0.56	0.1	0.04	0.2	0.26	-0.39	0.08	0.06	-0.31	0.24	-0.24	0.23	-0.13	0.2	-0.35	-0.02
Accounts Payable	0.91	0.59	0.69	0.18		0.7	0.84	0.93	0.12	0.71	-0.63	0.59	0.75	0.82	0.6	0.28	-0.62	0.77	0.74	0.34	-0.35	-0.55	0.64	-0.6	0.66	-0.59
Net Receivables	0.59	0.87	0.33	0.36	0.7		0.46	0.64	0.14	0.44	-0.79	0.72	0.37	0.46	0.81	0.16	-0.33	0.39	0.57	0.21	-0.56	-0.37	0.39	-0.14	0.38	0.0
Total Liab	0.96	0.44	0.95	0.01	0.84	0.46		0.91	0.04	0.89	-0.4	0.55	0.96	0.98	0.41	0.44	-0.91	0.97	0.8	0.62	-0.21	-0.58	0.76	-0.88	0.79	-0.61
Total Current Assets	0.97	0.63	0.75	0.25	0.93	0.64	0.91		0.05	0.84	-0.66	0.48	0.84	0.91	0.46	0.13	-0.74	0.85	0.72	0.52	-0.3	-0.5	0.68	-0.74	0.69	-0.61
Short Term Debt	0.04	0.13	0.04	-0.16	0.12	0.14	0.04	0.05		0.03	-0.18	0.31	-0.2	0.02	0.2	0.25	-0.09	-0.19	0.22	-0.42	-0.37	0.03	0.12	0.04	-0.16	0.24
Intangible Assets	0.92	0.59	0.86	0.31	0.71	0.44	0.89	0.84	0.03		-0.52	0.57	0.87	0.96	0.43	0.32	-0.91	0.88	0.59	0.72	-0.36	-0.4	0.56	-0.74	0.53	-0.41
Short Term Investments	-0.6	-0.85	-0.23	-0.56	-0.63	-0.79	-0.4	-0.66	-0.18	-0.52		-0.52	-0.28	-0.46	-0.7	0.16	0.29	-0.31	-0.37	-0.11	0.72	0.38	-0.11	0.1	-0.11	0.06
Common Stock	0.57	0.64	0.61	0.1	0.59	0.72	0.55	0.48	0.31	0.57	-0.52		0.46	0.53	0.88	0.72	-0.55	0.48	0.66	0.2	-0.62	-0.54	0.33	-0.2	0.33	0.02
Long Term Debt	0.91	0.35	0.94	0.04	0.75	0.37	0.96	0.84	-0.2	0.87	-0.28	0.46		0.95	0.33	0.43	-0.88	1.0	0.69	0.73	-0.09	-0.55	0.72	-0.86	0.79	-0.65
Good Will	0.97	0.53	0.92	0.2	0.82	0.46	0.98	0.91	0.02	0.96	-0.46	0.53	0.95		0.42	0.36	-0.9	0.96	0.7	0.7	-0.24	-0.5	0.72	-0.84	0.69	-0.58
Property Plant Equipment	0.52	0.77	0.39	0.26	0.6	0.81	0.41	0.46	0.2	0.43	-0.7	0.88	0.33	0.42		0.42	-0.32	0.35	0.61	0.12	-0.63	-0.65	0.3	-0.09	0.28	0.04
Current Deferred Revenue	0.3	-0.03	0.65	-0.39	0.28	0.16	0.44	0.13	0.25	0.32	0.16	0.72	0.43	0.36	0.42		-0.5	0.42	0.51	0.09	-0.21	-0.43	0.33	-0.26	0.34	-0.09
Net Tangible Assets	-0.83	-0.37	-0.94	0.08	-0.62	-0.33	-0.91	-0.74	-0.09	-0.91	0.29	-0.55	-0.88	-0.9	-0.32	-0.5		-0.89	-0.71	-0.7	0.3	0.46	-0.63	0.83	-0.68	0.34
Long Term Debt Total	0.92	0.38	0.94	0.06	0.77	0.39	0.97	0.85	-0.19	0.88	-0.31	0.48	1.0	0.96	0.35	0.42	-0.89		0.7	0.72	-0.11	-0.56	0.72	-0.86	0.78	-0.65
Capital Surpluse	0.74	0.44	0.73	-0.31	0.74	0.57	0.8	0.72	0.22	0.59	-0.37	0.66	0.69	0.7	0.61	0.51	-0.71	0.7		0.35	-0.25	-0.76	0.77	-0.73	0.86	-0.34
Deferred Long Term Liab	0.59	0.39	0.61	0.24	0.34	0.21	0.62	0.52	-0.42	0.72	-0.11	0.2	0.73	0.7	0.12	0.09	-0.7	0.72	0.35		0.08	-0.16	0.55	-0.66	0.57	-0.22
Accumulated Depreciation	-0.32	-0.57	-0.21	-0.24	-0.35	-0.56	-0.21	-0.3	-0.37	-0.36	0.72	-0.62	-0.09	-0.24	-0.63	-0.21	0.3	-0.11	-0.25	0.08		0.31	0.16	-0.15	0.1	-0.36
Short Long Term Debt	-0.56	-0.28	-0.58	0.23	-0.55	-0.37	-0.58	-0.5	0.03	-0.4	0.38	-0.54	-0.55	-0.5	-0.65	-0.43	0.46	-0.56	-0.76	-0.16	0.31		-0.42	0.47	-0.59	0.35
Cash And Equivalents	0.69	0.34	0.68	-0.13	0.64	0.39	0.76	0.68	0.12	0.56	-0.11	0.33	0.72	0.72	0.3	0.33	-0.63	0.72	0.77	0.55	0.16	-0.42		-0.84	0.85	-0.46
Net Invested Capital	-0.78	-0.18	-0.81	0.2	-0.6	-0.14	-0.88	-0.74	0.04	-0.74	0.1	-0.2	-0.86	-0.84	-0.09	-0.26	0.83	-0.86	-0.73	-0.66	-0.15	0.47	-0.84		-0.85	0.62
Net Working Capital	0.69	0.23	0.71	-0.35	0.66	0.38	0.79	0.69	-0.16	0.53	-0.11	0.33	0.79	0.69	0.28	0.34	-0.68	0.78	0.86	0.57	0.1	-0.59	0.85	-0.85		-0.49
Capital Stock	-0.6	0.06	-0.51	-0.02	-0.59	0.0	-0.61	-0.61	0.24	-0.41	0.06	0.02	-0.65	-0.58	0.04	-0.09	0.34	-0.65	-0.34	-0.22	-0.36	0.35	-0.46	0.62	-0.49

Click cells to compare fundamentals

Haemonetics Cash Per Share Historical Pattern

Today, most investors in Haemonetics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Haemonetics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's cash per share growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Haemonetics cash per share as a starting point in their analysis.

Haemonetics Cash Per Share

Timeline

Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.

Competition

Predict Haemonetics

Cash Per Share Over Time

Haemonetics Common Stock Shares Outstanding

Common Stock Shares Outstanding

42.56 Million

At present, Haemonetics' Common Stock Shares Outstanding is projected to decrease significantly based on the last few years of reporting.

In accordance with the recently published financial statements, Haemonetics has a Cash Per Share of 4.79 times. This is 10.11% higher than that of the Health Care Equipment & Supplies sector and 37.64% higher than that of the Health Care industry. The cash per share for all United States stocks is 4.39% higher than that of the company.

Haemonetics Cash Per Share Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Haemonetics' direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Haemonetics could also be used in its relative valuation, which is a method of valuing Haemonetics by comparing valuation metrics of similar companies.

Haemonetics is currently under evaluation in cash per share category among related companies.

Haemonetics Fundamentals

	Return On Equity	0.15
	Return On Asset	0.0612
	Profit Margin	0.1 %
	Operating Margin	0.16 %
	Current Valuation	5.47 B
	Shares Outstanding	50.79 M
	Shares Owned By Insiders	0.76 %
	Shares Owned By Institutions	99.24 %
	Number Of Shares Shorted	2.24 M
	Price To Earning	50.35 X
	Price To Book	4.59 X
	Price To Sales	3.41 X
	Revenue	1.17 B
	Gross Profit	530.77 M
	EBITDA	249.34 M
	Net Income	115.4 M
	Cash And Equivalents	284.47 M
	Cash Per Share	4.79 X
	Total Debt	765.89 M
	Debt To Equity	1.12 %
	Current Ratio	2.73 X
	Book Value Per Share	18.57 X
	Cash Flow From Operations	273.06 M
	Short Ratio	5.08 X
	Earnings Per Share	2.46 X
	Price To Earnings To Growth	1.63 X
	Target Price	105.57
	Number Of Employees	3.03 K
	Beta	0.36
	Market Capitalization	4.79 B
	Total Asset	1.93 B
	Retained Earnings	253.17 M
	Working Capital	517.91 M
	Current Asset	488.09 M
	Current Liabilities	185.55 M
	Net Asset	1.93 B

About Haemonetics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Haemonetics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Haemonetics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Haemonetics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Haemonetics Investors Sentiment

The influence of Haemonetics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Haemonetics. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.

Investor biases related to Haemonetics' public news can be used to forecast risks associated with an investment in Haemonetics. The trend in average sentiment can be used to explain how an investor holding Haemonetics can time the market purely based on public headlines and social activities around Haemonetics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.

Haemonetics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Haemonetics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Haemonetics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Haemonetics.

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Haemonetics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Haemonetics' short interest history, or implied volatility extrapolated from Haemonetics options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Haemonetics is a strong investment it is important to analyze Haemonetics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Haemonetics' future performance. For an informed investment choice regarding Haemonetics Stock, refer to the following important reports:

How To Invest In Haemonetics

Details

Is Haemonetics Stock a good investment?

Details

What is Haemonetics' Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out Haemonetics Piotroski F Score and Haemonetics Altman Z Score analysis.

For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.

Note that the Haemonetics information on this page should be used as a complementary analysis to other Haemonetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.

Complementary Tools for Haemonetics Stock analysis

When running Haemonetics' price analysis, check to measure Haemonetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Haemonetics is operating at the current time. Most of Haemonetics' value examination focuses on studying past and present price action to predict the probability of Haemonetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Haemonetics' price. Additionally, you may evaluate how the addition of Haemonetics to your portfolios can decrease your overall portfolio volatility.

	Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
	Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
	Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
	ETFs Find actively traded Exchange Traded Funds (ETF) from around the world
	Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges
	Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum
	Content Syndication Quickly integrate customizable finance content to your own investment portal
	Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios
	Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges
	Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges
	Technical Analysis Check basic technical indicators and analysis based on most latest market data

Is Haemonetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Haemonetics. If investors know Haemonetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Haemonetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.05)

Earnings Share

2.46

Revenue Per Share

25.092

Quarterly Revenue Growth

0.101

Return On Assets

0.0612

The market value of Haemonetics is measured differently than its book value, which is the value of Haemonetics that is recorded on the company's balance sheet. Investors also form their own opinion of Haemonetics' value that differs from its market value or its book value, called intrinsic value, which is Haemonetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Haemonetics' market value can be influenced by many factors that don't directly affect Haemonetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Haemonetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Haemonetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Haemonetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Haemonetics Stock Cash Per Share

Haemonetics Company Cash Per Share Analysis

Cash Per Share

Total Cash

Average Shares

Current Haemonetics Cash Per Share

Haemonetics Cash Per Share Driver Correlations

Haemonetics Cash Per Share Historical Pattern

Haemonetics Common Stock Shares Outstanding

Common Stock Shares Outstanding

42.56 Million

Haemonetics Cash Per Share Peer Comparison

Haemonetics Fundamentals

About Haemonetics Fundamental Analysis

Haemonetics Investors Sentiment

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Haemonetics Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY